Venkat Rajasurya
Pulmonary Disease · Winston Salem, NCNPI 1669601662
Payments from drug & device makers
Across 14 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$123
- Sanofi-aventis U.S. LLC$57
- GSK$44
- Sanofi$23
- La Jolla Pharmaceutical Company$22
- Insmed, Inc.$22
- plus $93 from 6 others
What the payments were for
- Food & beverage$22859%
- Education$15641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| GSK | 2 | $44 |
| Sanofi | 1 | $23 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Insmed, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
| AstraZeneca | 1 | $13 |
How this compares
$385 in reported general payments places this provider in the 30th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 460 | $370,482 |
| Dupixent PenDupilumab | 25 | $93,266 |
| Breo ElliptaFluticasone/Vilanterol | 148 | $81,624 |
| XolairOmalizumab | 24 | $77,964 |
| Advair HfaFluticasone Propion/Salmeterol | 109 | $63,175 |
| Spiriva HandihalerTiotropium Bromide | 57 | $59,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $32,266 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 203 | $31,909 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $27,614 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $25,119 |
| Spiriva RespimatTiotropium Bromide | 26 | $24,636 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $20,458 |
| Arnuity ElliptaFluticasone Furoate | 50 | $15,024 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 384 | $12,011 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $11,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $44 | $498,814720 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $13 | $62,807123 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $20 | $49,75577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Winston Salem
- Wendy MooreWinston Salem$892K
- Eugene BleeckerWinston Salem$739K
- Jill OharWinston Salem$558K
- Kapilkumar PatelWinston Salem$480K
- Chad MarionWinston Salem$265K
- Victor OrtegaWinston Salem$150K
- Andrew NamenWinston Salem$119K
- Jessica FieldWinston Salem$71K
- Daniel FilesWinston Salem$69K
- Karl ThomasWinston Salem$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.